Utama › Karsinoma Nasofaring › Georgia
Kajian klinikal Karsinoma Nasofaring di Georgia
6 kajian untuk Karsinoma Nasofaring sedang mencari peserta di lokasi di Georgia.
Bandar di Georgia
Teks kajian rasmi (Bahasa Inggeris)
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Emory University Hospital Midtown, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Emory University Hospital Midtown, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Mengambil pesertaFasa 2
Sehingga umur 21 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06064097Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT06662058TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mac 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Feb 2026 · NCT06636734Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.